Nacubactam

Nacubactam (OP0595 free acid) is a potent non-β-lactam-β-lactamase inhibitor with activity against class A and C β-lactamases. Nacubactam acts as a penicillin binding protein (PBP) 2-active antibacterial, and gives β-lactamase-independent potentiation of β-lactams targeting other PBPs. Nacubactam potentiates the antimicrobial activities of Piperacillin (HY-B1923), Cefepime (HY-B0692), and Meropenem (HY-13678) against CTX-M-15-positive Escherichia coli and KPC-positive Klebsiella pneumoniae[1][2][3][4][5][6].

Product Specifications

CAS Number

[1452458-86-4]

Product Name Alternative

OP0595 (free acid)

UNSPSC

12352005

Hazard Statement

H302

Target

Bacterial; Beta-lactamase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/nacubactam.html

Purity

99.30

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(ON1[C@]2([H])CC[C@@H](C(NOCCN)=O)[N@@](C2)C1=O)(O)=O

Molecular Formula

C9H16N4O7S

Molecular Weight

324.31

Precautions

H302

References & Citations

[1]Morinaka A, et al. In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016 Apr 22;60 (5) :3001-6.|[2]Monogue ML, et al. In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model. Antimicrob Agents Chemother. 2018 Aug 27;62 (9) :e02596-17.|[3]Misawa K, et al. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. Int J Antimicrob Agents. 2022 Nov-Dec;60 (5-6) :106669.|[4]Kaushik A, et al. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2019 Aug 23;63 (9) :e00733-19.|[5]Barnes MD, et al. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. Antimicrob Agents Chemother. 2019 Jul 25;63 (8) :e00432-19. |[6]Livermore DM, et al. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J Antimicrob Chemother. 2015 Nov;70 (11) :3032-41.